Details of the Drug

General Information of Drug (ID: DMAK85L)

Drug Name
Natalizumab
Indication
Disease Entry ICD 11 Status REF
Crohn disease DD70 Approved [1]
Multiple sclerosis 8A40 Approved [1]
Affected Organisms
Humans and other mammals
ATC Code
L04AA23: Natalizumab
L04AA: Selective immunosuppressants
L04A: IMMUNOSUPPRESSANTS
L04: IMMUNOSUPPRESSANTS
L: ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
Drug Type
Monoclonal antibody
Cross-matching ID
UNII
3JB47N2Q2P
DrugBank ID
DB00108
TTD ID
D3LWJ7
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Integrin alpha-4 (ITGA4) TT4BT06 ITA4_HUMAN Not Available [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Crohn disease
ICD Disease Classification DD70
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Integrin alpha-4 (ITGA4) DTT ITGA4 9.70E-14 1.52 7.72
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 FDA Approved Drug Products from FDA Official Website.
2 Natalizumab in Multiple Sclerosis Treatment: From Biological Effects to Immune Monitoring. Front Immunol. 2020 Sep 24;11:549842.